ClinicalTrials.gg
CompletedNCT05169905Updated Apr 7, 2023Results posted

A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

A Phase 3 interventional study of RSV MAT vaccine and dTpa vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 2 sites in United States. Open to female participants aged 9 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-07.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
9 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline — 1 open to participants now, 5 under way, 3 of them phase 3. Respiratory Syncytial Virus Infections · GlaxoSmithKline.

Enrollment
38th of 40
9 · median 642
Started
2022
with 4 others
Phase 3
21 of 40
none open now
Registered
23rd of 40
by date

Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 38th largest by enrollment, is one of 5 that started in 2022, is one of 21 in phase 3, and was the 23rd registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 9 Years to 49 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the reactogenicity, safety and immune response of a single intramuscular dose of the respiratory syncytial virus maternal (RSV MAT) vaccine in healthy non-pregnant girls 9-17 years of age (YOA) compared to non-pregnant adult women 18-49 YOA. The combined reduced-antigen-content diphtheria, tetanus and acellular pertussis (dTpa) vaccine was planned to be used as an active control for safety and reactogenicity evaluation.

Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009), GSK made the decision to stop enrolment and vaccination in this study. Enrolled study participants were monitored as part of the study until study completion.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory Syncytial Virus Maternal vaccine
  • Combined reduced-antigen-content diphtheria, tetanus and acellular pertussis vaccine
  • Reactogenicity
  • Safety
  • Immunogenicity
  • Healthy non-pregnant girl
  • Healthy non-pregnant adult women
04

Who can participate

Ages eligible
9 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy Non-pregnant Adult Women from 18-49 YOA

  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written or witnessed/thumb printed obtained from the participant prior to performance of any study-specific procedure.
  • A healthy female participant, as established by medical history and clinical examination, between and including 18 to 49 YOA at the time of the first study intervention administration.
  • (based on participant's report) 17.0 to 39.9 kg/m\^2, inclusive for adult participants.
  • Female participants of may be enrolled in the study, if the participant:

    • has practiced adequate for 1 month prior to study intervention administration, and
    • has a negative pregnancy test on the day of study intervention administration, and
    • has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administrations.
  • Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or .

Healthy non-pregnant Girls from 9-17 YOA

  • Participants and participants' parent(s)/Legally Acceptable Representative(s) (LAR), who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written or witnessed/thumb printed informed consent obtained from the participant*/parent(s)/LAR(s) of the participant prior to performance of any study-specific procedure.

    • *Written informed consent obtained from parents/LARs and written informed assent obtained from the participant if she is less than legal age. The legal age is determined according to local regulations in each participating country.
    • In case the legal age is achieved during the conduct of the study, an additional written informed consent from the participant should be obtained at the time of the legal age.
  • A healthy female participant between and including 9 and 17 YOA at the time of the first study intervention administration.

    • Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, or bilateral ovariectomy.
  • Body mass index by age between 5 percentile and 95 percentile (inclusive) for pediatric participants.
  • Female participants of childbearing potential may be enrolled in the study, if the participant:

    • has a negative pregnancy test on the day of study intervention administration, and is abstinent during the entire treatment period and for 1 month before and after completion of the study intervention administration series (and if so, this is to be documented in the source documents at each vaccination visit)
    • or has practiced adequate contraception for 1 month prior to study intervention administration and has agreed to continue adequate contraception during the entire treatment period and for 1 month after completion of the study intervention administration series.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Any clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
  • History of any reaction or likely to be exacerbated by any component of the study intervention(s).
  • Any confirmed or suspected or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
  • Current disorder (based on medical history and physical examination), for which the participant has received immune-modifying therapy within 6 months, before study vaccination.
  • Hypersensitivity to latex.
  • Acute or chronic abnormality or poorly controlled pre-existent co-morbidities or any other clinical conditions, as determined by physical examination or medical history that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
  • Significant or uncontrolled psychiatric illness.
  • Documented (HIV)-positive participant.
  • Any clinically significant* hematological parameter and/or biochemical laboratory abnormality from the test requested by the investigator based on medical judgment prior to enrolment

    • *The investigator should use his/her clinical judgment to decide whether the test is needed, and which abnormalities are clinically significant. If he/she decides to run this test, the investigator will need to review the test results before proceeding with the administration of the study vaccine.
  • Lymphoproliferative disorder or within 5 years before study vaccination (excluding effectively treated non-melanoma skin cancer).

Prior/Concomitant therapy

  • Use of any or non-registered product (drug, vaccine or medical device) other than the study intervention(s) during the period beginning 30 days before the first doses (Day -29 to Day 1), or their planned use during the study period.
  • Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before the first dose and ending 30 days after the last dose of study intervention(s)* administration with the exception of any licensed influenza vaccine which may be administered ≥ 15 days before or after study vaccinations (dTpa and RSV maternal vaccines).

    • *In case emergency mass vaccination for an unforeseen public health threat (e.g. a pandemic) is organized by public health authorities outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine (if it is used according to the local governmental recommendations and that the Sponsor is notified accordingly). Therefore, COVID-19 vaccines will be allowed, when administered ≥ 15 days before or after study vaccinations (dTpa and RSV maternal vaccines).
  • Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab).
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the administration of the first dose of study intervention(s) or planned administration during the study period.
  • Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 3 months prior to the first study intervention dose(s) to 2 months after first vaccination. For , this will mean prednisone equivalent ≥5 mg/day for adult participants/ ≥0.5 mg/kg/day. Inhaled and topical steroids are allowed.
  • Previous experimental vaccination against RSV.
  • Boostrix (dTpa) administration for which the vaccination is not aligned with the local recommendations for dTap vaccination or not aligned with the locally approved Boostrix (dTpa) prescribing information.

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device).

Other exclusions

  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue precautions.
  • Alcoholism or substance use disorder within the past 24 months based on the presence of two or more of the following abuse criteria: hazardous use, social/interpersonal problems related to use, neglected major roles to use, withdrawal tolerance, use of larger amounts or longer, repeated attempts to quit or control use, much time spent using, physical or psychological problems related to use, activities given up to use, craving.
  • Any study personnel or their immediate dependents, family, or household members.
  • Child in care.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    RSV_dTpa-P Group

    Healthy non-pregnant girls 9-17 years of age received a single dose of RSV MAT vaccine at Day 1 and were scheduled to receive a single dose of dTpa vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration). Participants who were enrolled and were due to receive the dTpa vaccine at Day 31, did no longer receive the dTpa as part of this study, but they were provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization.

    Combination Product: RSV MAT vaccine · Combination Product: dTpa vaccine

  • Experimental
    dTpa_RSV-P Group

    Healthy non-pregnant girls 9-17 years of age were scheduled to receive a single dose of dTpa vaccine at Day 1 and a single dose of RSV MAT vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration), but there were no participants assigned to this study group, and hence, there was no vaccine administered in this study group.

    Combination Product: RSV MAT vaccine · Combination Product: dTpa vaccine

  • Experimental
    RSV_dTpa-A Group

    Healthy non-pregnant adult women 18-49 years of age received a single dose of RSV MAT vaccine at Day 1 and were scheduled to receive a single dose of dTpa vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration). Participants who were enrolled and were due to receive the dTpa vaccine at Day 31, did no longer receive the dTpa as part of this study, but they were provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization.

    Combination Product: RSV MAT vaccine · Combination Product: dTpa vaccine

  • Experimental
    dTpa_RSV-A Group

    Healthy non-pregnant adult women 18-49 years of age received a single dose of dTpa vaccine at Day 1 and were scheduled to receive a single dose of RSV MAT vaccine at Day 31 and to be followed-up until end of study (180 days post-vaccine administration). RSV MAT vaccine was no longer administered to participants at Day 31.

    Combination Product: RSV MAT vaccine · Combination Product: dTpa vaccine

Interventions

  • Combination productRSV MAT vaccine

    Single dose of the RSV MAT vaccine reconstituted with NaCl solution was planned to be administered intramuscularly, in the non-dominant arm, at Day 1 or at Day 31, depending on the vaccination schedule. RSV MAT vaccine was no longer administered to participants at Day 31. No vaccine was administered in the dTpa_RSV-P Group, since there were no participants assigned to it.

  • Combination productdTpa vaccine

    Single dose of the dTpa vaccine was planned to be administered intramuscularly, in the non-dominant arm, at Day 1 or at Day 31, depending on the vaccination schedule. Two formulations of dTpa vaccine are licensed in the US and outside of the US (ex-US), respectively. dTpa-US formulation was administered to participants in centers located in the US, while dTpa-ex-US formulation was planned to be administered to participants in centers ex-US. The dTpa-ex-US formulation was not applicable in this study anymore as no non-US sites were initiated before the decision to stop the study. The participants in RSV_dTpa-P and RSV_dTpa-A study groups were provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization. No vaccine was administered in the dTpa_RSV-P Group, since there were no participants assigned to it.

    Also known as: Boostrix

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Any Serious Adverse Events (SAEs)

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in abnormal pregnancy outcomes. Any is defined as the occurrence of the symptom regardless of intensity grade or relationship to vaccination.

    Time frame: During the entire study period (from Day 1 up to Day 181)

  2. Number of Participants Reporting Adverse Events (AEs)/SAEs Leading to Study Withdrawal

    An AE is any untoward medical occurrence, symptom, or disease in a clinical study participant that is temporally associated with the study intervention. The AE may or may not be considered related to the study intervention. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in abnormal pregnancy outcomes. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for him/her since the date of withdrawal/last contact.

    Time frame: During the entire study period (from Day 1 up to Day 181)

  3. Number of Participants Reporting Any Solicited Administration Site Events

    Assessed solicited administration site events include pain, erythema and swelling. Any pain = occurrence of the symptom regardless of intensity grade. Any erythema and swelling = symptom reported with a surface diameter lower than or equal to 20 millimeters.

    Time frame: During the 7 days follow-up period post-Dose 1

  4. Number of Participants Reporting Any Solicited Systemic Events

    Assessed solicited systemic events include fatigue, headache, gastrointestinal (GI) symptoms (nausea, vomiting, diarrhea, abdominal pain) and fever. The preferred location for measuring temperature is the oral cavity. Fever is defined as temperature equal to or above (≥) 38.0 °C/100.4°F. Any is defined as the occurrence of the symptom regardless of intensity grade.

    Time frame: During the 7 days follow-up period post-Dose 1

  5. Number of Participants Reporting Any Unsolicited AEs

    An unsolicited AE is an event reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event. Any is defined as the occurrence of the unsolicited AE regardless of intensity grade or relationship to vaccination.

    Time frame: During the 30 days follow-up period post-Dose 1

  6. Number of Participants Reporting SAEs and Medically Attended Adverse Events (MAEs)

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in abnormal pregnancy outcomes. An MAE is an unsolicited AE for which the participants receive medical attention, defined as symptoms or illnesses requiring a hospitalization, or an emergency room visit, or visit to/by a health care provider.

    Time frame: During the 30 days follow-up period post-Dose 1

  7. Number of Participants Reporting AEs/SAEs/MAEs Leading to Study Withdrawal

    An AE is any untoward medical occurrence, symptom, or disease in a clinical study participant that is temporally associated with the study intervention. The AE may or may not be considered related to the study intervention. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in abnormal pregnancy outcomes. An MAE is an unsolicited AE for which the participants received medical attention defined as symptoms or illnesses requiring a hospitalization, or an emergency room visit, or visit to/by a health care provider. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for him/her since the date of withdrawal/last contact.

    Time frame: During the 30 days follow-up period post-Dose 1

Secondary outcomes

  1. RSV-A Neutralizing Antibody Titers for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 1

    RSV-A neutralizing antibody titer expressed in Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60) is presented for each participant who received the RSV MAT vaccine and was assigned to the respective group.

    Time frame: At pre-dosing (Day 1)

  2. RSV-A Neutralizing Antibody Titers for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 31

    RSV-A neutralizing antibody titer expressed in ED60 is presented for each participant who received the RSV MAT vaccine and was assigned to the respective group.

    Time frame: At 30 days post-RSV MAT vaccine administration (Day 31)

  3. RSV-B Neutralizing Antibody Titers for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 1

    RSV-B neutralizing antibody titer expressed in ED60 is presented for each participant who received the RSV MAT vaccine and was assigned to the respective group.

    Time frame: At pre-dosing (Day 1)

  4. RSV-B Neutralizing Antibody Titers for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 31

    RSV-B neutralizing antibody titer expressed in ED60 is presented for each participant who received the RSV MAT vaccine and was assigned to the respective group.

    Time frame: At 30 days post-RSV MAT vaccine administration (Day 31)

  5. RSV MAT Immunoglobulin G (IgG) Antibody Concentrations for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 1

    RSV MAT IgG antibody concentration expressed in ELISA units per milliliter (EU/mL) is presented for each participant who received the RSV MAT vaccine and was assigned to the respective group.

    Time frame: At pre-dosing (Day 1)

  6. RSV MAT IgG Antibody Concentrations for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 31

    RSV MAT IgG antibody concentration expressed in EU/mL is presented for each participant who received the RSV MAT vaccine and was assigned to the respective group.

    Time frame: At 30 days post-RSV MAT vaccine administration (Day 31)

07

Results

Posted Apr 7, 2023

Participant flow

The study was planned to enroll 252 participants in 4 groups as per Protocol. However, due to early stoppage of enrolment and further vaccination, only 9 participants were enrolled in the study, out of which 8 participants were assigned to individual groups, except for the dTpa_RSV-P group, hence this group was not included in the results record.

Participant flow — Overall Study
MilestoneRSV_dTpa-P GroupRSV_dTpa-A GroupdTpa_RSV-A Group
Started134
Completed134
Not completed000

Outcome measures

PrimaryNumber of Participants Reporting Any Serious Adverse Events (SAEs)

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in abnormal pregnancy outcomes. Any is defined as the occurrence of the symptom regardless of intensity grade or relationship to vaccination.

Time frame:
During the entire study period (from Day 1 up to Day 181)
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Serious Adverse Events (SAEs)
ParticipantsRSV_dTpa-P GroupRSV_dTpa-A GroupdTpa_RSV-A Group
Number of Participants Reporting Any Serious Adverse Events (SAEs)000
PrimaryNumber of Participants Reporting Adverse Events (AEs)/SAEs Leading to Study Withdrawal

An AE is any untoward medical occurrence, symptom, or disease in a clinical study participant that is temporally associated with the study intervention. The AE may or may not be considered related to the study intervention. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in abnormal pregnancy outcomes. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for him/her since the date of withdrawal/last contact.

Time frame:
During the entire study period (from Day 1 up to Day 181)
Reported as:
Count of participants · Participants
Number of Participants Reporting Adverse Events (AEs)/SAEs Leading to Study Withdrawal
ParticipantsRSV_dTpa-P GroupRSV_dTpa-A GroupdTpa_RSV-A Group
Number of Participants Reporting Adverse Events (AEs)/SAEs Leading to Study Withdrawal000
PrimaryNumber of Participants Reporting Any Solicited Administration Site Events

Assessed solicited administration site events include pain, erythema and swelling. Any pain = occurrence of the symptom regardless of intensity grade. Any erythema and swelling = symptom reported with a surface diameter lower than or equal to 20 millimeters.

Time frame:
During the 7 days follow-up period post-Dose 1
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Administration Site Events
ParticipantsRSV_dTpa-P GroupRSV_dTpa-A GroupdTpa_RSV-A Group
Pain113
Erythema001
Swelling000
PrimaryNumber of Participants Reporting Any Solicited Systemic Events

Assessed solicited systemic events include fatigue, headache, gastrointestinal (GI) symptoms (nausea, vomiting, diarrhea, abdominal pain) and fever. The preferred location for measuring temperature is the oral cavity. Fever is defined as temperature equal to or above (≥) 38.0 °C/100.4°F. Any is defined as the occurrence of the symptom regardless of intensity grade.

Time frame:
During the 7 days follow-up period post-Dose 1
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Systemic Events
ParticipantsRSV_dTpa-P GroupRSV_dTpa-A GroupdTpa_RSV-A Group
Fatigue011
Headache012
Nausea010
Vomiting000
Diarrhea022
Abdominal pain010
Fever000
PrimaryNumber of Participants Reporting Any Unsolicited AEs

An unsolicited AE is an event reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event. Any is defined as the occurrence of the unsolicited AE regardless of intensity grade or relationship to vaccination.

Time frame:
During the 30 days follow-up period post-Dose 1
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Unsolicited AEs
ParticipantsRSV_dTpa-P GroupRSV_dTpa-A GroupdTpa_RSV-A Group
Number of Participants Reporting Any Unsolicited AEs011
PrimaryNumber of Participants Reporting SAEs and Medically Attended Adverse Events (MAEs)

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in abnormal pregnancy outcomes. An MAE is an unsolicited AE for which the participants receive medical attention, defined as symptoms or illnesses requiring a hospitalization, or an emergency room visit, or visit to/by a health care provider.

Time frame:
During the 30 days follow-up period post-Dose 1
Reported as:
Count of participants · Participants
Number of Participants Reporting SAEs and Medically Attended Adverse Events (MAEs)
ParticipantsRSV_dTpa-P GroupRSV_dTpa-A GroupdTpa_RSV-A Group
Number of Participants Reporting SAEs and Medically Attended Adverse Events (MAEs)000
PrimaryNumber of Participants Reporting AEs/SAEs/MAEs Leading to Study Withdrawal

An AE is any untoward medical occurrence, symptom, or disease in a clinical study participant that is temporally associated with the study intervention. The AE may or may not be considered related to the study intervention. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant or results in abnormal pregnancy outcomes. An MAE is an unsolicited AE for which the participants received medical attention defined as symptoms or illnesses requiring a hospitalization, or an emergency room visit, or visit to/by a health care provider. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for him/her since the date of withdrawal/last contact.

Time frame:
During the 30 days follow-up period post-Dose 1
Reported as:
Count of participants · Participants
Number of Participants Reporting AEs/SAEs/MAEs Leading to Study Withdrawal
ParticipantsRSV_dTpa-P GroupRSV_dTpa-A GroupdTpa_RSV-A Group
Number of Participants Reporting AEs/SAEs/MAEs Leading to Study Withdrawal000
SecondaryRSV-A Neutralizing Antibody Titers for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 1

RSV-A neutralizing antibody titer expressed in Estimated Dose: serum dilution giving a 60% reduction of the signal compared to a control without serum (ED60) is presented for each participant who received the RSV MAT vaccine and was assigned to the respective group.

Time frame:
At pre-dosing (Day 1)
Reported as:
Number · Titers (ED60)
RSV-A Neutralizing Antibody Titers for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 1
Titers (ED60)RSV_dTpa-P GroupRSV_dTpa-A Group
Participant 1861355
Participant 2—792
Participant 3—177
SecondaryRSV-A Neutralizing Antibody Titers for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 31

RSV-A neutralizing antibody titer expressed in ED60 is presented for each participant who received the RSV MAT vaccine and was assigned to the respective group.

Time frame:
At 30 days post-RSV MAT vaccine administration (Day 31)
Reported as:
Number · Titers (ED60)
RSV-A Neutralizing Antibody Titers for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 31
Titers (ED60)RSV_dTpa-P GroupRSV_dTpa-A Group
Participant 1170221707
Participant 2—38258
Participant 3—17765
SecondaryRSV-B Neutralizing Antibody Titers for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 1

RSV-B neutralizing antibody titer expressed in ED60 is presented for each participant who received the RSV MAT vaccine and was assigned to the respective group.

Time frame:
At pre-dosing (Day 1)
Reported as:
Number · Titers (ED60)
RSV-B Neutralizing Antibody Titers for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 1
Titers (ED60)RSV_dTpa-P GroupRSV_dTpa-A Group
Participant 13732434
Participant 2—525
Participant 3—461
SecondaryRSV-B Neutralizing Antibody Titers for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 31

RSV-B neutralizing antibody titer expressed in ED60 is presented for each participant who received the RSV MAT vaccine and was assigned to the respective group.

Time frame:
At 30 days post-RSV MAT vaccine administration (Day 31)
Reported as:
Number · Titers (ED60)
RSV-B Neutralizing Antibody Titers for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 31
Titers (ED60)RSV_dTpa-P GroupRSV_dTpa-A Group
Participant 12089138336
Participant 2—14233
Participant 3—34743
SecondaryRSV MAT Immunoglobulin G (IgG) Antibody Concentrations for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 1

RSV MAT IgG antibody concentration expressed in ELISA units per milliliter (EU/mL) is presented for each participant who received the RSV MAT vaccine and was assigned to the respective group.

Time frame:
At pre-dosing (Day 1)
Reported as:
Number · EU/mL
RSV MAT Immunoglobulin G (IgG) Antibody Concentrations for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 1
EU/mLRSV_dTpa-P GroupRSV_dTpa-A Group
Participant 119494967
Participant 2—3279
Participant 3—4727
SecondaryRSV MAT IgG Antibody Concentrations for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 31

RSV MAT IgG antibody concentration expressed in EU/mL is presented for each participant who received the RSV MAT vaccine and was assigned to the respective group.

Time frame:
At 30 days post-RSV MAT vaccine administration (Day 31)
Reported as:
Number · EU/mL
RSV MAT IgG Antibody Concentrations for Participants in RSV_dTpa-P Group and RSV_dTpa-A Group at Day 31
EU/mLRSV_dTpa-P GroupRSV_dTpa-A Group
Participant 150193149510
Participant 2—218190
Participant 3—402812

Adverse events

Collected over Solicited AEs were collected during the 7-day follow-up period after vaccination. Unsolicited AEs were collected during the 30-day follow-up period after vaccination. SAEs were collected from study start (Day 1) up to 180 days after vaccination (Day 181).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RSV_dTpa-P Group0/1 (0%)0/1 (0%)1/1 (100%)
RSV_dTpa-A Group0/3 (0%)0/3 (0%)2/3 (66.7%)
dTpa_RSV-A Group0/4 (0%)0/4 (0%)3/4 (75%)
Most frequent other events
Most frequent other events
EventRSV_dTpa-P GroupRSV_dTpa-A GroupdTpa_RSV-A Group
Administration site painGeneral disorders1/11/33/4
DiarrhoeaGastrointestinal disorders0/12/32/4
HeadacheNervous system disorders0/11/32/4
FatigueGeneral disorders0/11/31/4
Abdominal painGastrointestinal disorders0/11/30/4
NauseaGastrointestinal disorders0/11/30/4
HypomenorrhoeaReproductive system and breast disorders0/11/30/4
Administration site erythemaGeneral disorders0/10/31/4
Intermenstrual bleedingReproductive system and breast disorders0/10/31/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RSV_dTpa-P GroupRSV_dTpa-A GroupdTpa_RSV-A GroupTotal
MeanNA ± NA42.3 ± 2.538.0 ± 9.439.9 ± 7.2
Sex: Female, Male
Sex: Female, Male(Participants)RSV_dTpa-P GroupRSV_dTpa-A GroupdTpa_RSV-A GroupTotal
Female1348
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RSV_dTpa-P GroupRSV_dTpa-A GroupdTpa_RSV-A GroupTotal
BLACK OR AFRICAN AMERICAN1001
WHITE0347
08

Study locations

2 sites
  • GSK Investigational Site
    Miami, Florida 33142, United States
  • GSK Investigational Site
    Beaumont, Texas 77706, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, a key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Aug 2022, 6 months.

Results were first posted in Apr 2023, 8 months after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 6 months is below that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2021
First posted
Dec 27, 2021
StartActual
Feb 2, 2022
Primary completionActual
Aug 3, 2022
CompletionActual
Aug 3, 2022
Results first posted
Apr 7, 2023
Last update
Apr 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05169905
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 27, 2021
Start date
Feb 2, 2022
Primary completion
Aug 3, 2022
Completion
Aug 3, 2022
Results posted
Apr 7, 2023
Last update
Apr 7, 2023

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Boostrix

Start the discussion